Status:

NOT_YET_RECRUITING

The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer

Lead Sponsor:

The Second Affiliated Hospital of Shandong First Medical University

Conditions:

Biliary Tract Neoplasms

Pancreatic Neoplasms

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Evaluate the efficacy and safety of Trilaciclib for myeloprotection prior to chemotherapy in advanced cholangiocarcinoma or pancreatic cancer.

Eligibility Criteria

Inclusion

  • Age \>18 years, male or female.
  • Pathologically confirmed diagnosis of cholangiocarcinoma or pancreatic cancer requiring chemotherapy-based treatment.
  • ECOG performance status ≥0 (or 1), anticipated survival ≥3 months, and ability to complete ≥3 months of follow-up.
  • No clinically significant abnormalities in complete blood count, hepatic/renal function, cardiac enzymes, or electrocardiogram (ECG).
  • Voluntary participation with good compliance and willingness to undergo safety and survival follow-up.
  • Signed written informed consent form prior to enrollment.

Exclusion

  • History of myeloid leukemia, myelodysplastic syndrome, or concurrent sickle cell disease.
  • Symptomatic CNS metastases and/or leptomeningeal disease requiring immediate radiotherapy or steroid therapy.
  • Major surgery or radiotherapy within 4 weeks prior to the first dose of study drug.
  • History of interstitial lung disease, slowly progressive dyspnea with dry cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis, multiple allergies, or peripheral arterial disease.
  • Concurrent requirement for radiotherapy.
  • Known hypersensitivity to any component of the study drug formulation.
  • Pregnancy or lactation.
  • Any other condition deemed by the investigator to compromise patient safety or study validity.

Key Trial Info

Start Date :

September 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2028

Estimated Enrollment :

96 Patients enrolled

Trial Details

Trial ID

NCT07160283

Start Date

September 1 2025

End Date

September 1 2028

Last Update

September 8 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.